Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Connect Biopharma (CNTB) reported positive preliminary topline Phase 2 data for rademikibart as add-on treatment for acute asthma exacerbations with type 2 inflammation.
The randomized, double-blind, placebo-controlled Seabreeze STAT Asthma study enrolled 160 participants, dosed 600 mg subcutaneously plus standard of care versus placebo. Rademikibart achieved a statistically significant improvement in post-bronchodilator FEV1 at Day 7, with a mean increase of 250 mL versus 120 mL on placebo (130 mL difference; p=0.023). Treatment failure over 28 days was reduced by approximately 66% versus placebo (p=0.153), and emergency department or unscheduled medical visits for worsening asthma were reduced by 50%. Rademikibart was well tolerated, with safety comparable to placebo and fewer serious adverse events. Phase 2 COPD data are expected later this month, after which the company plans FDA discussions on a Phase 3 program.
Connect Biopharma (CNTB) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11:30 a.m. ET.
The live webcast will be accessible through the Investors section of the company’s website, and an archived replay will remain available online for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) reported second quarter 2026 results, highlighting completion of enrollment in its Phase 2 Seabreeze STAT asthma (160 patients) and COPD (159 patients) studies of rademikibart for acute exacerbations, with topline data expected in September 2026 and a planned FDA meeting to discuss a potential Phase 3 program.
In August 2026, the company began the Seabreeze STAT IV Phase 2 study to bridge 600 mg subcutaneous to 300 mg IV dosing. License and collaboration revenue rose to $2.8 million for Q2 2026, mainly from a Simcere regulatory milestone. Q2 research and development expense increased to $16.3 million, general and administrative expense declined to $4.1 million, and net loss widened to $17.3 million or ($0.27) per share. Cash, cash equivalents and short-term investments were $31.5 million, which the company expects to fund operations for at least one year from this release date.
Connect Biopharma (Nasdaq:CNTB) completed enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart for acute asthma exacerbations in patients with type 2 inflammation. The company is on track to complete enrollment in the related COPD study this month and expects topline asthma data in early September 2026.
According to Connect Biopharma, topline COPD data are expected soon after, with plans to meet the FDA in 2026 to align on a Phase 3 program. The company reports a strong balance sheet with cash runway into the second half of 2027.
Connect Biopharma (Nasdaq:CNTB) announced that management will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 9:30 a.m. ET.
A live webcast and a replay for about 90 days will be available in the Investors section of the company website.
Connect Biopharma (Nasdaq:CNTB) reported Q1 2026 results and a business update focused on rademikibart in asthma, COPD and atopic dermatitis.
Phase 2 Seabreeze STAT trials continue with topline data expected mid‑2026. The company closed a $20.2 million private placement and ended Q1 with $46.0 million in cash, guiding runway into 2H 2027.
Connect Biopharma (NASDAQ: CNTB) reported that the independent Data Monitoring Committee completed a pre-specified interim efficacy review of its Phase 2 Seabreeze STAT asthma and COPD studies of rademikibart and made no recommendation to change sample size.
The DMC indicated no safety concerns, cited no treatment-related serious or severe adverse events, and enrollment will continue as planned. Topline data from both studies are expected mid-2026, and the company plans to meet with the FDA to align on a Phase 3 program.
Connect Biopharma (NASDAQ: CNTB) reported 2025 results and a business update on March 31, 2026. Key items: positive Phase 1 IV rademikibart topline with rapid FEV1 gains (~200–400 mL maintained to Day 29); Phase 3 AD results showed near‑maximal responses in ~90% through 52 weeks; Phase 2 Seabreeze STAT studies ongoing with toplines mid‑2026.
Corporate: entered a $20.2M private placement (6,130,000 shares at $3.25); cash $44.3M at Dec 31, 2025; expected runway into H2 2027. FY2025 net loss $55.5M; R&D $37.8M; license revenues $64k; eligible milestones ~ $110M.
Connect Biopharma (Nasdaq: CNTB) agreed to sell 6,130,000 ordinary shares in a private placement at $3.25 per share, expected to raise gross proceeds of approximately $20.2 million.
The financing, led by Panacea Venture with Leerink Partners and Cantor as joint placement agents, is expected to close on or about March 31, 2026 and extend the company’s cash runway into the second half of 2027. Net proceeds will fund R&D, development programs, working capital and general corporate purposes.
Connect Biopharma (Nasdaq: CNTB) reported Phase 3 RADIANT-AD results for rademikibart, presented at AAD 2026. In a 52-week trial (n=259), rademikibart achieved durable responses: EASI-75 96.6%, IGA 0/1 87.1%, and EASI-90 85.3%, with safety comparable to placebo and low conjunctivitis rates.
The study used 300 mg SC every two weeks with a 16-week induction and 36-week maintenance phase; company to host a March 30, 2026 webcast and call.